Corbus Pharmaceuticals Holdings, Inc.
CRBP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.7% and free cash flow fell 78.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CRBP
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Altman Z-score
Corbus Pharmaceuticals Holdings, Inc.'s Altman Z-score for fiscal 2021 is −4.15, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2021 | −4.15 | 2.20 |
| FY2020 | −6.35 | (1.36) |
| FY2019 | −4.99 | (8.41) |
| FY2018 | 3.42 | (17.89) |
| FY2017 | 21.31 | 3.69 |
| FY2016 | 17.62 | 12.46 |
| FY2015 | 5.15 | — |
How fiscal 2021’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.77 | — | 0.93 | |
| Retained earnings / total assets | (3.25) | — | −4.54 | |
| EBIT / total assets | (0.52) | — | −1.72 | |
| Market value of equity / total liabilities | 1.96 | — | 1.18 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Distress zone | −4.15 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −7.13 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CLLS Cellectis S.A. compare | 0.0× |
| RLYB Rallybio Corporation compare | −3.1× |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | −4.1× |
| EQ Equillium, Inc. compare | −6.8× |
| KZIA Novogen Limited compare | −39.9× |
| PMN Promis Neurosciences compare | −78.9× |
| AARD Aardvark Therapeutics, Inc. compare | — |
| NMRA Neumora Therapeutics, Inc. compare | — |
| OKUR OnKure Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets